eJHaem (May 2022)

Anti‐SARS‐CoV‐2 vaccines in recipient and/or donor before allotransplant

  • Maxime Jullien,
  • Marianne Coste‐Burel,
  • Beatrice Clemenceau,
  • Valentin Letailleur,
  • Thierry Guillaume,
  • Pierre Peterlin,
  • Alice Garnier,
  • Amandine Le Bourgeois,
  • Berthe‐Marie Imbert,
  • Jocelyn Ollier,
  • Audrey Grain,
  • Cyrille Touzeau,
  • Philippe Moreau,
  • Marie C Béné,
  • Henri Vié,
  • Patrice Chevallier

DOI
https://doi.org/10.1002/jha2.398
Journal volume & issue
Vol. 3, no. 2
pp. 484 – 487

Abstract

Read online

Abstract The impact of pre‐transplant anti‐severe acute respiratory syndrome coronavirus‐2 (SARS‐CoV‐2) vaccine in 20 recipients of allogeneic hematopoietic stem cell transplantation (Allo‐HSCT) and/or their donors is reported here, showing that the persistence of anti‐SARS‐CoV‐2 antibodies can be detected in almost all patients, whatever the type of vaccine used, and up to 9 months post transplant. Also, an anti‐SARS‐CoV‐2 spike glycoprotein CD3+ T‐cell response could be detected in six (35%) of 17 evaluable patients. This study provides a rationale to consider anti‐SARS‐CoV‐2 vaccination of both recipients and donors before Allo‐HSCT.

Keywords